By Molecule Class, Semaglutide Leads Today but Cedes Leadership by 2035 Semaglutide holds a commanding 58% share of the obesity GLP-1 market in 2025, underpinned by robust clinical validation from the STEPandSELECT trials, proven cardiovascular benefits, and extensive real-world use
However, individuals with medical conditions, allergies, or sensitive skin should consult their physician before starting
Research has shown that GLP-1s effectively reduce blood glucose in people with type 2 diabetes
Gene therapy approaches: Early research exploring ways to turn the body into its own GLP-1 factory
NordicTrack assumes no responsibility for any personal injury or damage sustained by any recommendations, opinions, or advice given in this article
These findings underscore the importance of considering demographic factors when evaluating the safety and efficacy of GLP-1 RAs in clinical practice